Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors
The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This leads to inhibition of phosphorylation of the RB family of proteins and subsequent association with E2Fs and formation of the DREAM complex thereby leading to a cell cycle arrest (Chen et al., 1996; Whittaker et al., 2017; Wiedemeyer, 2018).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Wiedemeyer, 2018
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Malumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,487
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2
Lee, M. G., & Nurse, P. (1987) · Nature · doi:10.1038/327031a0 · Cited by 1,140
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
Forging a signature of in vivo senescence
Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104
Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021
The INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K., Lee, J.-H., Ciarallo, S., Catzavelos, C., Beniston, R., et al. (2002) · Nature Medicine · doi:10.1038/nm761 · Cited by 948
Expression of transcription factor E2F1 induces quiescent cells to enter S phase
Johnson, D. G., Schwarz, J. K., Cress, W. D., & Nevins, J. R. (1993) · Nature · doi:10.1038/365349a0 · Cited by 943
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., & Roberts, J. M. (1997) · Nature Medicine · doi:10.1038/nm0297-222 · Cited by 901
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Lawson, D. A., Bhakta, N. R., Kessenbrock, K., Prummel, K. D., Yu, Y., Takai, K., Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.-Y., et al. (2015) · Nature · doi:10.1038/nature15260 · Cited by 893
Genetic control of cell size at cell division in yeast
Nurse, P. (1975) · Nature · doi:10.1038/256547a0 · Cited by 861
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
ERK implication in cell cycle regulation
Chambard, J.-C., Lefloch, R., Pouysségur, J., & Lenormand, P. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.010 · Cited by 750
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Early dissemination seeds metastasis in breast cancer
Hosseini, H., Obradović, M. M. S., Hoffmann, M., Harper, K. L., Sosa, M. S., Werner-Klein, M., Nanduri, L. K., Werno, C., Ehrl, C., Maneck, M., et al. (2016) · Nature · doi:10.1038/nature20785 · Cited by 740
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700
Mutual exclusivity analysis identifies oncogenic network modules
Ciriello, G., Cerami, E., Sander, C., & Schultz, N. (2012) · Genome Research · doi:10.1101/gr.125567.111 · Cited by 675
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., et al. (2008) · Nature · doi:10.1038/nature07179 · Cited by 672
The E2F1–3 transcription factors are essential for cellular proliferation
Wu, L., Timmers, C., Maiti, B., Saavedra, H. I., Sang, L., Chong, G. T., Nuckolls, F., Giangrande, P., Wright, F. A., Field, S. J., et al. (2001) · Nature · doi:10.1038/35106593 · Cited by 625
Pocket proteins and cell cycle control
Cobrinik, D. (2005) · Oncogene · doi:10.1038/sj.onc.1208619 · Cited by 601
E2F target genes: unraveling the biology
Bracken, A. P., Ciro, M., Cocito, A., & Helin, K. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.06.006 · Cited by 576
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A. (2001) · Nature · doi:10.1038/35092584 · Cited by 568
Mechanism of early dissemination and metastasis in Her2+ mammary cancer
Harper, K. L., Sosa, M. S., Entenberg, D., Hosseini, H., Cheung, J. F., Nobre, R., Avivar-Valderas, A., Nagi, C., Girnius, N., Davis, R. J., et al. (2016) · Nature · doi:10.1038/nature20609 · Cited by 562
Genetic Control of the Cell-Division Cycle in Yeast, I. Detection of Mutants
Hartwell, L. H., Culotti, J., & Reid, B. (1970) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.66.2.352 · Cited by 561
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
Cyclin E in normal and neoplastic cell cycles
Hwang, H. C., & Clurman, B. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208613 · Cited by 514
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.063 · Cited by 465
Inside and out: the activities of senescence in cancer
Pérez-Mancera, P. A., Young, A. R. J., & Narita, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3773 · Cited by 462
Prall, O. J., Sarcevic, B., Musgrove, E. A., Watts, C. W., & Sutherland, R. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10882 · Cited by 444
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0300 · Cited by 444
Keating, J. T., Čviko, A., Riethdorf, S., Riethdorf, L., Quade, B. J., Sun, D., Duensing, S., Sheets, E. E., Münger, K., & Crum, C. P. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200107000-00006 · Cited by 430
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
Functionally homologous cell cycle control genes in budding and fission yeast
Beach, D., Durkacz, B., & Nurse, P. (1982) · Nature · doi:10.1038/300706a0 · Cited by 412
Targeting WEE1 Kinase in Cancer
Matheson, C. J., Backos, D. S., & Reigan, P. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.006 · Cited by 408
Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5476 · Cited by 399
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Cdc2–cyclin E complexes regulate the G1/S phase transition
Aleem, E., Kiyokawa, H., & Kaldis, P. (2005) · Nature Cell Biology · doi:10.1038/ncb1284 · Cited by 383
p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2
Chu, I., Sun, J., Arnaout, A., Kahn, H., Hanna, W., Narod, S., Sun, P., Tan, C.-K., Hengst, L., & Slingerland, J. (2007) · Cell · doi:10.1016/j.cell.2006.11.049 · Cited by 372
Cellular senescence: putting the paradoxes in perspective
Campisi, J. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.005 · Cited by 368
Secrets of a double agent: CDK7 in cell-cycle control and transcription
Fisher, R. P. (2005) · Journal of Cell Science · doi:10.1242/jcs.02718 · Cited by 363
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
Cdk-Inhibitory Activity and Stability of p27 Are Directly Regulated by Oncogenic Tyrosine Kinases
Grimmler, M., Wang, Y., Mund, T., Cilenšek, Z., Keidel, E.-M., Waddell, M. B., Jäkel, H., Kullmann, M., Kriwacki, R. W., & Hengst, L. (2007) · Cell · doi:10.1016/j.cell.2006.11.047 · Cited by 337
Draetta, G., Brizuela, L., Potashkin, J., & Beach, D. (1987) · Cell · doi:10.1016/0092-8674(87)90227-3 · Cited by 337
The INK4 family of cell cycle inhibitors in cancer
Roussel, M. F. (1999) · Oncogene · doi:10.1038/sj.onc.1202998 · Cited by 322
Michaud, K., Solomon, D. A., Oermann, E., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 319
Lukas, J., Petersen, B. O., Holm, K., Bartek, J., & Helin, K. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1047 · Cited by 303
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Konecny, G. E., Winterhoff, B., Kolarova, T., Qi, J., Manivong, K., Dering, J., Yang, G., Chalukya, M., Wang, H.-J., Anderson, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2307 · Cited by 302
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
E2F1 represses β-catenin transcription and is antagonized by both pRB and CDK8
Morris, E. J., Ji, J.-Y., Yang, F., Di Stefano, L., Herr, A., Moon, N.-S., Kwon, E.-J., Haigis, K. M., Näär, A. M., & Dyson, N. J. (2008) · Nature · doi:10.1038/nature07310 · Cited by 297
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Cell Cycle Control of Wnt Receptor Activation
Davidson, G., Shen, J., Huang, Y.-L., Su, Y., Karaulanov, E., Bartscherer, K., Hassler, C., Stannek, P., Boutros, M., & Niehrs, C. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.11.006 · Cited by 275
Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0098 · Cited by 273
Larochelle, S., Merrick, K. A., Terret, M.-E., Wohlbold, L., Barboza, N. M., Zhang, C., Shokat, K. M., Jallepalli, P. V., & Fisher, R. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.003 · Cited by 268
Misra, R. N., Xiao, H.-Y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 252
Kumar, S. K., LaPlant, B., Chng, W. J., Zonder, J., Callander, N., Fonseca, R., Fruth, B., Roy, V., Erlichman, C., & Stewart, A. K. (2015) · Blood · doi:10.1182/blood-2014-05-573741 · Cited by 252
E2f1–3 switch from activators in progenitor cells to repressors in differentiating cells
Chong, J.-L., Wenzel, P. L., Sáenz-Robles, M. T., Nair, V., Ferrey, A., Hagan, J. P., Gomez, Y. M., Sharma, N., Chen, H.-Z., Ouseph, M., et al. (2009) · Nature · doi:10.1038/nature08677 · Cited by 248
Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses
Kuhn, E., Wu, R.-C., Guan, B., Wu, G., Zhang, J., Wang, Y., Song, L., Yuan, X., Wei, L., Roden, R. B. S., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs345 · Cited by 247
Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K.-M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2653 · Cited by 244
Cellular substrates of p34cdc2 and its companion cyclin-dependent kinases
Nigg, E. A. (1993) · Trends in Cell Biology · doi:10.1016/0962-8924(93)90011-o · Cited by 231
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Sánchez-Martínez, C., Gelbert, L. M., Lallena, M. J., & de Dios, A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.100 · Cited by 230
Synthetic lethality between CCNE1 amplification and loss of BRCA1
Etemadmoghadam, D., Weir, B. A., Au-Yeung, G., Alsop, K., Mitchell, G., George, J., Australian Ovarian Cancer Study Group, Davis, S., D’Andrea, A. D., Simpson, K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314302110 · Cited by 225
Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225
Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1
Martín, A., Odajima, J., Hunt, S. L., Dubus, P., Ortega, S., Malumbres, M., & Barbacid, M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.006 · Cited by 223
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001613107 · Cited by 223
Self-citationCoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer
Leiserson, M. D., Wu, H.-T., Vandin, F., & Raphael, B. J. (2015) · Genome Biology · doi:10.1186/s13059-015-0700-7 · Cited by 210
Karst, A. M., Jones, P. M., Vena, N., Ligon, A. H., Liu, J. F., Hirsch, M. S., Etemadmoghadam, D., Bowtell, D. D. L., & Drapkin, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2247 · Cited by 208
Nakayama, N., Nakayama, K., Shamima, Y., Ishikawa, M., Katagiri, A., Iida, K., & Miyazaki, K. (2010) · Cancer · doi:10.1002/cncr.24987 · Cited by 201
A Predictive Scale for Evaluating Cyclin-dependent Kinase Substrates
Holmes, J. K., & Solomon, M. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.41.25240 · Cited by 201
Chen, R., Wierda, W. G., Chubb, S., Hawtin, R. E., Fox, J. A., Keating, M. J., Gandhi, V., & Plunkett, W. (2009) · Blood · doi:10.1182/blood-2008-12-190256 · Cited by 196
Finn, R. S., Crown, J. P., Ettl, J., Schmidt, M., Bondarenko, I. M., Lang, I., Pinter, T., Boer, K., Patel, R., Randolph, S., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0721-5 · Cited by 186
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Paruch, K., Dwyer, M. P., Alvarez, C., Brown, C., Chan, T.-Y., Doll, R. J., Keertikar, K., Knutson, C., McKittrick, B., Rivera, J., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100051d · Cited by 175
A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression
Schachter, M. M., Merrick, K. A., Larochelle, S., Hirschi, A., Zhang, C., Shokat, K. M., Rubin, S. M., & Fisher, R. P. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.04.003 · Cited by 169
Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41402 · Cited by 168
Laoukili, J., Alvarez, M., Meijer, L. A. T., Stahl, M., Mohammed, S., Kleij, L., Heck, A. J. R., & Medema, R. H. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01710-07 · Cited by 163
Malorni, L., Piazza, S., Ciani, Y., Guarducci, C., Bonechi, M., Biagioni, C., Hart, C. D., Verardo, R., Leo, A. D., & Migliaccio, I. (2016) · Oncotarget · doi:10.18632/oncotarget.12010 · Cited by 162
Mita, M. M., Joy, A. A., Mita, A. C., Sankhala, K. K., Jou, Y., Zhang, D., Statkevich, P., Zhu, Y., Yao, S., Small, K. A., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.016 · Cited by 156
Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells
Hollenhorst, P. C., Ferris, M. W., Hull, M. A., Chae, H., Kim, S., & Graves, B. J. (2011) · Genes & Development · doi:10.1101/gad.17546311 · Cited by 154
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
Cyclin E overexpression and amplification in human tumours
Schraml, P., Bucher, C., Bissig, H., Nocito, A., Haas, P., Wilber, K., Seelig, S., Kononen, J., Mihatsch, M. J., Dirnhofer, S., et al. (2003) · The Journal of Pathology · doi:10.1002/path.1356 · Cited by 152
Caldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A., Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0963 · Cited by 151
Au-Yeung, G., Lang, F., Azar, W. J., Mitchell, C., Jarman, K. E., Lackovic, K., Aziz, D., Cullinane, C., Pearson, R. B., Mileshkin, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0620 · Cited by 146
Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3364 · Cited by 142
Wang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007) · Blood · doi:10.1182/blood-2007-02-071266 · Cited by 134
Conroy, A., Stockett, D. E., Walker, D. H., Arkin, M. R., Hoch, U., Fox, J. A., & Hawtin, R. E. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0921-5 · Cited by 131
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
Regulation of BRCA1 Expression by the Rb-E2F Pathway
Wang, A., Schneider-Broussard, R., Kumar, A. P., MacLeod, M. C., & Johnson, D. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.4532 · Cited by 123
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
Taylor‐Harding, B., Aspuria, P.-J. P., Agadjanian, H., Cheon, D., Mizuno, T., Greenberg, D. N., Allen, J. R., Spurka, L., Funari, V. A., Spiteri, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2673 · Cited by 122
Self-citationOncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
Bilke, S., Schwentner, R., Yang, F., Kauer, M. O., Jug, G., Walker, R. L., Davis, S. R., Zhu, Y. J., Pineda, M. A., Meltzer, P. S., et al. (2013) · Genome Research · doi:10.1101/gr.151340.112 · Cited by 122
Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development
Wiedemeyer, R., Brennan, C., Heffernan, T. P., Xiao, Y., Mahoney, J., Protopopov, A., Zheng, H., Bignell, G., Furnari, F., Cavenee, W. K., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.010 · Cited by 119
Zhu, Y. X., Tiedemann, R. E., Shi, C.-X., Yin, H., Schmidt, J. E., Bruins, L. A., Keats, J. J., Braggio, E., Sereduk, C., Mousses, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-304022 · Cited by 118
Etemadmoghadam, D., Au-Yeung, G., Wall, M., Mitchell, C., Kansara, M., Loehrer, E., Batzios, C., George, J., Ftouni, S., Weir, B. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1337 · Cited by 117
Heath, E. I., Bible, K. C., Martell, R. E., Adelman, D. C., & LoRusso, P. M. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9090-3 · Cited by 114
Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
Kryštof, V., Baumli, S., & Fürst, R. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800672750 · Cited by 112
Lodén, M., Stighall, M., Nielsen, N. H., Roos, G., Emdin, S. O., Östlund, H., & Landberg, G. (2002) · Oncogene · doi:10.1038/sj.onc.1205578 · Cited by 107
Etemadmoghadam, D., George, J., Cowin, P. A., Cullinane, C., Kansara, M., Australian Ovarian Cancer Study Group, Gorringe, K. L., Smyth, G. K., & Bowtell, D. D. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015498 · Cited by 105
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
Yang, L., Fang, D., Chen, H., Lu, Y., Dong, Z., Ding, H.-F., Jing, Q., Su, S.-B., & Huang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4600 · Cited by 98
Cyclin E as a potential therapeutic target in high grade serous ovarian cancer
Kanska, J. E., Zakhour, M., Taylor‐Harding, B., Karlan, B. Y., & Wiedemeyer, W. R. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.111 · Cited by 98
Self-citationNasmyth, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00604-3 · Cited by 93
Nakayama, H., Okumura, S., Daisaki, H., Kato, Y., Uehara, H., Adachi, S., Yoshimura, M., & Okada, M. (2010) · Cancer · doi:10.1002/cncr.25244 · Cited by 91
Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma
Kuhn, E., Bahadirli-Talbott, A., & Shih, I. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.209 · Cited by 79
Sherr, C. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00486-x · Cited by 78
Alagpulinsa, D. A., Ayyadevara, S., Yaccoby, S., & Shmookler Reis, R. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0660 · Cited by 74
Chiron, D., Martin, P., Di Liberto, M., Huang, X., Ely, S., Lannutti, B. J., Leonard, J. P., Mason, C. E., & Chen-Kiang, S. (2013) · Cell Cycle · doi:10.4161/cc.24928 · Cited by 71
Wiedemeyer, W. R., Beach, J. A., & Karlan, B. Y. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00034 · Cited by 71
Self-citationHamza, A., Tammpere, E., Kofoed, M., Keong, C., Chiang, J., Giaever, G., Nislow, C., & Hieter, P. (2015) · Genetics · doi:10.1534/genetics.115.181099 · Cited by 69
Chen, X., Xie, F., Zhu, X.-J., Lin, F., Pan, S.-S., Gong, L.-H., Qiu, J.-G., Zhang, W., Jiang, Q., Mei, X.-L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3717 · Cited by 66
A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence
Acevedo, M., Vernier, M., Mignacca, L., Lessard, F., Huot, G., Moiseeva, O., Bourdeau, V., & Ferbeyre, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2347 · Cited by 66
The CDK-activating kinase Cdk7: Taking yes for an answer
Schachter, M. M., & Fisher, R. P. (2013) · Cell Cycle · doi:10.4161/cc.26355 · Cited by 56
Sotillo, R., Renner, O., Dubus, P., Ruiz-Cabello, J., Martín-Caballero, J., Barbacid, M., Carnero, A., & Malumbres, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4195 · Cited by 53
Gyanchandani, R., Kota, K. J., Jonnalagadda, A. R., Minteer, T., Knapick, B. A., Oesterreich, S., Brufsky, A., Lee, A. V., & Puhalla, S. L. (2016) · Oncotarget · doi:10.18632/oncotarget.11383 · Cited by 50
The cancer drug that almost wasn't
Garber, K. (2014) · Science · doi:10.1126/science.345.6199.865 · Cited by 25
Cited by
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
Aging of the cells: Insight into cellular senescence and detection Methods.
Mohamad Kamal, N. S., Safuan, S., Shamsuddin, S., & Foroozandeh, P. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151108 · Cited by 287
Muthamil, S., Kim, H., Jang, H., Lyu, J., Shin, U. C., Go, Y., Park, S., Lee, H. G., & Park, J. H. (2024) · Advanced Biology · doi:10.1002/adbi.202400079 · Cited by 98
Cellular senescence and abdominal aortic aneurysm: From pathogenesis to therapeutics
Wang, D., Hao, X., Jia, L., Jing, Y., Jiang, B., & Xin, S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.999465 · Cited by 19
Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 – 2019)
Wang, P., Qiu, H., He, Y., & Zhu, H. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1825686 · Cited by 10
Metadata
- Authors
- Wiedemeyer, W. R.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Wiedemeyer, Wolf Ruprecht
- Venue
- Resistance to Targeted Anti-Cancer Therapeutics
- Publisher
- Springer International Publishing
- Published
- 2018
- Pages
- 181-210
- ISSN
- 2196-5501 (ISSN-L)
- 2196-551X
- OpenAlex
- W2795296107
- Cited by
- 7
- References
- 133
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 2
- FWCI
- 4.12
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Resistance to targeted anti-cancer therapeutics (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- cyclin-dependent kinase inhibitors, CDK4/6 inhibitors, acquired drug resistance, palbociclib, ribociclib, abemaciclib, dinaciclib, hormone receptor-positive breast cancer, estrogen receptor-positive breast cancer, MAPK signaling, PI3K signaling, RB1 mutation, cell cycle dysregulation, combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.